TEVA: Teva Pharmaceuticals Growth-Adjusted Payback Ratio

Symbol and logo of brand tevapharm.com (TEVA)

Steady growth in branded drug sales has provided Teva Pharmaceutical Industries (TEVA) with high liquidity. The GURU.Markets service features a PEG ratio chart, where the latest value is recorded as 2.22. While quotes depend on fierce pricing competition in the generics segment, competent management is successfully reducing debt and introducing new biosimilars, effectively managing anti-crisis processes.

TEVA Teva Pharmaceutical Industries Ltd. Price/Earnings to Growth Ratio (07/04/2022 - 11/17/2026)

Analytical breakdowns for Teva Pharmaceutical Industries Limited (TEVA)

- share price and consensus valuation forecast:
- market capitalization information:
Fundamental company analysis:Teva Pharmaceutical Industries Ltd. (TEVA)
Manufactured products of Teva Pharmaceuticals

The PEG ratio determines investment attractiveness by comparing a company's market value to its net income growth rate, where a value below one indicates an undervalued asset. By analyzing historical PEG levels, an investor can gauge the scaling efficiency of Teva Pharmaceutical Industries (TEVA), whose dominance in the generics segment and control over active pharmaceutical ingredient production ensure low costs and sustainable profit growth.